Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Yu K, et al. Cancer Biol Ther. 2008 Feb;7(2):307-15. doi: 10.4161/cbt.7.2.5334. Epub 2007 Nov 21. Cancer Biol Ther. 2008. PMID: 18059185
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.
Shor B, Wu J, Shakey Q, Toral-Barza L, Shi C, Follettie M, Yu K. Shor B, et al. Among authors: yu k. J Biol Chem. 2010 May 14;285(20):15380-92. doi: 10.1074/jbc.M109.071639. Epub 2010 Mar 16. J Biol Chem. 2010. PMID: 20233713 Free PMC article.
Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Chen Z, Venkatesan AM, Dehnhardt CM, Ayral-Kaloustian S, Brooijmans N, Mallon R, Feldberg L, Hollander I, Lucas J, Yu K, Kong F, Mansour TS. Chen Z, et al. Among authors: yu k. J Med Chem. 2010 Apr 22;53(8):3169-82. doi: 10.1021/jm901783v. J Med Chem. 2010. PMID: 20334367
Identification of pyrimidine derivatives as hSMG-1 inhibitors.
Gopalsamy A, Bennett EM, Shi M, Zhang WG, Bard J, Yu K. Gopalsamy A, et al. Among authors: yu k. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41. doi: 10.1016/j.bmcl.2012.08.107. Epub 2012 Sep 7. Bioorg Med Chem Lett. 2012. PMID: 23021994
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J, Chen Y, Meng T, Ma L, Meng L, Wang X, Yu T, Zask A, Shen J, Yu K. Qian J, et al. Among authors: yu t, yu k. Oncotarget. 2016 Oct 11;7(41):67071-67086. doi: 10.18632/oncotarget.11490. Oncotarget. 2016. PMID: 27563814 Free PMC article.
Isolation and structure of homotemsirolimuses A, B, and C.
Kong F, Zhu T, Yu K, Pagano TG, Desai P, Radebaugh G, Fawzi M. Kong F, et al. Among authors: yu k. J Nat Prod. 2011 Apr 25;74(4):547-53. doi: 10.1021/np1003388. Epub 2011 Mar 25. J Nat Prod. 2011. PMID: 21438579
mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.
Chen Y, Qian J, He Q, Zhao H, Toral-Barza L, Shi C, Zhang X, Wu J, Yu K. Chen Y, et al. Among authors: yu k. Oncotarget. 2016 May 3;7(18):25224-40. doi: 10.18632/oncotarget.8279. Oncotarget. 2016. PMID: 27015560 Free PMC article.
Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R. Dehnhardt CM, et al. Among authors: yu k. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4773-8. doi: 10.1016/j.bmcl.2011.06.063. Epub 2011 Jun 21. Bioorg Med Chem Lett. 2011. PMID: 21763134
5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer.
Zhang N, Ayral-Kaloustian S, Anderson JT, Nguyen T, Das S, Venkatesan AM, Brooijmans N, Lucas J, Yu K, Hollander I, Mallon R. Zhang N, et al. Among authors: yu k. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3526-9. doi: 10.1016/j.bmcl.2010.04.139. Epub 2010 May 17. Bioorg Med Chem Lett. 2010. PMID: 20483602
Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
Zask A, Verheijen JC, Richard DJ, Kaplan J, Curran K, Toral-Barza L, Lucas J, Hollander I, Yu K. Zask A, et al. Among authors: yu k. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2644-7. doi: 10.1016/j.bmcl.2010.02.045. Epub 2010 Feb 13. Bioorg Med Chem Lett. 2010. PMID: 20227881